Survival Benefit Shown With IA Gemcitabine in Patients with Locally Advanced Pancreatic Cancer

Logo - Targeted Oncology

Prolonged progression-free survival (PFS) has been demonstrated with intra-arterial (IA) administration of gemcitabine (RenovoGem) in patients with locally advanced pancreatic cancer (LAPC), according to interim findings from the pivotal phase 3 TIGeR-PaC study (NCT03257033).1

Results presented during the 2023 European Society of Medical Oncology (ESMO) World Congress on Gastrointestinal Cancer showed that in 23 patients, the median 8-month PFS was 15 months with RenovoGem compared with 7 months with the standard of care combination of gemcitabine plus nab-paclitaxel. In terms of overall survival (OS), the primary end point of the study, RenovoGem achieved a median OS of 16 months vs 10 months with gemcitabine/nab-paclitaxel. The OS results excluded roughly 5.5 months of life from the time of diagnosis to randomization during the induction chemotherapy and radiation phase of the study, according to a press release by RenovoRx.

View the entire article on Targeted Oncology

Previous Post
Intra-Arterial Gemcitabine Extends PFS in Locally Advanced Pancreatic Cancer
Next Post
RenovoRx’s TAMP Platform Will Deliver Imugene’s CF33 Oncolytic Virotherapy in Companies’ Research Collaboration